(The Yates Network) While checkpoint inhibitor therapies (CPIs) have revolutionized the treatment of many cancers, the majority of patients do not respond. TGFβ has been implicated in primary resistance to checkpoints but development of therapies targeting broad TGFβ signaling has been hindered by dose-limiting cardiotoxicities. Preclinical data demonstrate highly selective inhibition of TGFβ1 activation with SRK-181 overcomes primary resistance to CPIs and leads to tumor regression or control, survival benefit, while avoiding the cardiotoxicities.

Original source: https://www.eurekalert.org/pub_releases/2020-03/tyn-opr032520.php